Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 20:13:923106.
doi: 10.3389/fimmu.2022.923106. eCollection 2022.

The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials

Robert L Murphy  1   2 , Eustache Paramithiotis  3 , Scott Sugden  3 , Todd Chermak  3 , Bruce Lambert  1 , Damien Montamat-Sicotte  3 , John Mattison  4 , Steve Steinhubl  5
Affiliations

The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials

Robert L Murphy et al. Front Immunol. .

Abstract

First-generation anit-SARS-CoV-2 vaccines were highly successful. They rapidly met an unforeseen emergency need, saved millions of lives, and simultaneously eased the burden on healthcare systems worldwide. The first-generation vaccines, however, focused too narrowly on antibody-based immunity as the sole marker of vaccine trial success, resulting in large knowledge gaps about waning vaccine protection, lack of vaccine robustness to viral mutation, and lack of efficacy in immunocompromised populations. Detailed reviews of first-generation vaccines, including their mode of action and geographical distribution, have been published elsewhere. Second-generation clinical trials must address these gaps by evaluating a broader range of immune markers, including those representing cell-mediated immunity, to ensure the most protective and long-lasting vaccines are brought to market.

Keywords: COVID - 19; SARS – CoV – 2; cellular immunity; immune profiling; vaccine trial design; vaccines.

PubMed Disclaimer

Conflict of interest statement

Authors EP, SSu, TC and DM-S were employed by company CellCarta. Authors TC and JM were employed by company Arsenal Capital. Author SSt was employed by company physIQ. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Vaisman-Mentesh A, Dror Y, Tur-Kaspa R, Markovitch D, Kournos T, Dicker D, et al. . SARS-CoV-2 specific memory b cells frequency in recovered patient remains stable while antibodies decay over time. Infect Dis (except HIV/AIDS) (2020). doi: 10.1101/2020.08.23.20179796 - DOI
    1. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. . Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (2021) 371:eabf4063. doi: 10.1126/science.abf4063 - DOI - PMC - PubMed
    1. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. . Distinct antibody and memory b cell responses in SARS-CoV-2 naïve and recovered individuals after mRNA vaccination. Sci Immunol (2021) 6:eabi6950. doi: 10.1126/sciimmunol.abi6950 - DOI - PMC - PubMed
    1. Fenwick C, Turelli P, Pellaton C, Farina A, Campos J, Raclot C, et al. . A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma. Sci Transl Med (2021) 13(605):eabi8452. doi: 10.1126/scitranslmed.abi8452. - DOI - PMC - PubMed
    1. Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19–associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance — VISION network, 10 states, august 2021–January 2022 . Available at: www.cdc.gov/mmwr/volumes/71/wr/mm7107e2.htm (Accessed April 1st 2022). - PMC - PubMed

Publication types

Substances